Project Grant R01AR087992
Award Date 8/5/26
Completion Date 5/31/31
Dollars Obligated $510K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $614,390 to the University of Georgia Research Foundation on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of human myogenesis, specifically the role of the CHAMP1 gene in muscle development and CHAMP1 syndrome. The research focuses on myoblast fusion, an essential process for muscle development and regeneration. Prior...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Arizona $578,565 on July 10, 2026, to investigate the role of skeletal myosin binding protein-C in distal arthrogryposis under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). Distal arthrogryposis is a genetic skeletal muscle disorder characterized by congenital joint contractures, muscle weakness, and reduced mobility with significant clinical morbidity. No...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $124,875 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate muscle-to-bone communication during fracture repair and musculoskeletal regeneration. The research identifies pro-regenerative signals from injured muscle that orchestrate repair of both bone and muscle tissue. Preliminary findings...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (part of the National Institutes of Health) awarded the University of California, Los Angeles $150,152 on March 27, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize migratory cell differentiation in developing zebrafish skin. The research will use live imaging, antibody staining, single-cell RNA sequencing, and pseudotime analysis to characterize the development of...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Wisconsin System $164,000 on December 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund research into the role of the protein SKNAC in mechanically induced skeletal muscle growth. The research investigates signaling pathways that promote muscle mass preservation and growth in response to mechanical loading....
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health under the Department of Health and Human Services, awarded $585,012 to Massachusetts General Hospital on June 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research investigating the role of the C10ORF10/DEPP1 protein in skeletal muscle atrophy. The recipient will conduct three specific aims: defining the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor University $503,834 on August 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate whether pharmacologic activation of satellite cells can prevent chemotherapy-induced delays in skeletal muscle growth and development in pediatric cancer patients. The research addresses the understudied adverse effects of CHOP chemotherapy (cyclophosphamide,...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $151,040 to The University of Texas Southwestern Medical Center on April 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop muscle-optimized non-viral gene editors for Duchenne muscular dystrophy. The project addresses limitations in lipid nanoparticle (LNP) delivery of CRISPR gene editing to skeletal muscle by designing gene editors that improve myonuclear...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Northstar Genomics, LLC $286,415 on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The Phase 1 research project aims to enhance the efficiency of generating human skeletal muscle in pigs for reconstructive and transplantation-based surgeries to treat skeletal muscle loss from trauma, surgery, and deep burns. The recipient's current approach uses somatic...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Missouri System $350,561 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The Project Grant (R21AR086497) funds research into syndecan-4's role in regulating satellite cell activity through dynamic multiprotein complexes. The research examines how syndecan-4 mediates myogenic progression—the transition of satellite cells from...